Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Sara Hurvitz MD to its Scientific Advisory Board (SAB).
Dr Hurvitz is a Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Medical Director of Jonsson Comprehensive Cancer Center’s Clinical Research Unit at UCLA, co-director of the Santa Monica-UCLA Outpatient Oncology Practice, and director of the Breast Oncology Program at UCLA’s Division of Hematology-Oncology.
Dr Hurvitz specialises in breast cancer treatment and is involved in designing, implementing, and leading clinical trials to test new targeted therapies. This includes studies of the gene expression patterns in various breast cancer populations and evaluating these patterns to detect new subtypes of breast cancer that novel therapies may more accurately target.
For more information, download the attached PDF.
Download this document
